Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

Chun-ling Dai,1 Amit K. Tiwari,2 Chung-Pu Wu,3 Xiao-dong Su,1 Si-Rong Wang,2 Dong-geng Liu,1 Charles R. Ashby, Jr.,2 Yan Huang,1 Robert W. Robey,4 Yong-ju Liang,1 Li-ming Chen,1 Cheng-Jun Shi,1 Suresh V. Ambudkar,2 Zhe-Sheng Chen,1 and Li-wu Fu1

1State Key Laboratory for Oncology in South China, Cancer Center, Sun Yat-Sen University, Guangzhou, China; 2Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John’s University, Jamaica, New York; and 3Laboratory of Cell Biology and 4Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

Abstract

Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor receptor (Her-1 or ErB1) and Her-2. It is conceivable that lapatinib may inhibit the function of ATP-binding cassette (ABC) transporters by binding to their ATP-binding sites. The aim of this study was to investigate the ability of lapatinib to reverse tumor multidrug resistance (MDR) due to over-expression of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2) transporters. Our results showed that lapatinib significantly enhanced the sensitivity to ABCB1 or ABCG2 substrates in cells expressing these transporters, although a small synergetic effect was observed in combining lapatinib and conventional chemotherapeutic agents in parental sensitive MCF-7 or S1 cells. Lapatinib alone, however, did not significantly alter the sensitivity of non-ABCB1 or non-ABCG2 substrates in sensitive and resistant cells. Additionally, lapatinib significantly increased the accumulation of doxorubicin or mitoxantrone in ABCB1- or ABCG2-overexpressing cells and inhibited the transport of methotrexate and E2173G by ABCG2. Furthermore, lapatinib stimulated the ATPase activity of both ABCB1 and ABCG2 and inhibited the photolabeling of ABCB1 or ABCG2 with [125I]iodoarylazidoprazosin in a concentration-dependent manner. However, lapatinib did not affect the expression of these transporters at mRNA or protein levels. Importantly, lapatinib also strongly enhanced the effect of paclitaxel on the inhibition of growth of the ABCB1-overexpressing KBx200 cell xenografts in nude mice. Overall, we conclude that lapatinib reverses ABCB1- and ABCG2-mediated MDR by directly inhibiting their transport function. These findings may be useful for cancer combinational therapy with lapatinib in the clinic. [Cancer Res 2008;68(19):7905–14]

Introduction

Multidrug resistance (MDR) is a major obstacle to successful chemotherapy treatment. MDR often results due to overexpression of ATP-binding cassette (ABC) transporters. In the human genome, 48 different ABC transporters have been identified and are divided into seven subfamilies (A-G) based on sequence similarities (1). Thus far, the major members of the ABC transporters leading to MDR in cancer cells include ABC subfamily B member 1 (ABCB1; also called P-glycoprotein), ABC subfamily C members (ABCCs, MDR-associated proteins), and ABC subfamily G member 2 (ABCG2; also called breast cancer resistance protein, mitoxantrone resistance protein, and placenta-specific ABC transporter). These membrane proteins actively pump out a wide range of structurally and functionally diverse amphipathic anticancer drugs from the inside of tumor cells, thereby decreasing their intracellular drug accumulation and resulting in chemotherapeutic drug resistance (1–4). Furthermore, each transporter can translocate unique compounds in addition to some overlapping substrates (1). Drugs transported by ABCB1 include hydrophobic compounds, either uncharged or slightly positively charged, including most chemotherapeutic agents such as Vinca alkaloids, anthracyclines, epipodophyllotoxins, and taxanes (5). A few of the ABCB1 subfamily members have been shown to confer MDR to organic anion compounds and phase II metabolic products, as well as some natural product chemotherapeutic agents, antifolates, and nucleotide analogues (6). The spectrum of chemotherapeutic agents transported by ABCG2 includes anthracyclines, mitoxantrone, camptothecin-derived and indolocarbazole topoisomerase I inhibitors, methotrexate, and flavopiridol (7).

The ErB/Her family of receptor tyrosine kinases mediates the transphosphorylation of tyrosine residues in the cytoplasmic domain of tyrosine kinase receptors via homodimerization or heterodimerization on ligand activation (8). In human tumors, the epidermal growth factor receptor (EGFR; Her-1 or ErbB1) and the other three members of the EGFR family, human epidermal receptor type 2, 3, and 4 (Her-2, Her-3, and Her-4), are often overexpressed, dysregulated, or mutated, and these abnormal alterations of EGFR activate a series of intracellular protein kinase signaling pathways, such as the Ras/mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase, signal transducer and activator of transcription, protein kinase C, and phospholipase D pathways, promoting tumor growth and progression including the promotion of proliferation, angiogenesis, invasion, metastasis, and inhibition of apoptosis (8,9). Therefore, blockade of EGFR and/or Her-2 activation may be able to suppress cancer cell growth and
progression. Lapatinib (Tykerb, GW572016) is an orally active small molecule, which is a novel member of the family of kinase inhibitors that inhibits the tyrosine kinases of Her-2 and EGFR. In preclinical studies, lapatinib was not cross-resistant to trastuzumab (10, 11). In clinical studies, lapatinib in combination with capecitabine has shown promising results compared with capecitabine alone in a phase III trial of Her-2-positive metastatic breast cancer patients whose cancers become unresponsive to trastuzumab or to other therapies (12). Lapatinib in combination with tamoxifen effectively inhibited cell proliferation and restored tamoxifen sensitivity in estrogen receptor-positive breast cancer models with shown resistance to tamoxifen (13, 14). Several randomized phase I and II studies (EGF104383, EGF104535, EGF30001, EGF105767, EGF100161, and EGF1025801) are ongoing to compare paclitaxel/docetaxel plus lapatinib as first-line treatment for Her-2-overexpressing breast cancer patients. But the action and mechanisms underlying the lapatinib-induced chemosensitivity of conventional chemotherapeutic agents in cancer cells remain to be elucidated. Gefitinib, an inhibitor of the tyrosine kinase activity of Her-1, has been reported to interact with ABCG2 and ABCB1 and to reverse ABCB1- and/or ABCG2-mediated MDR by directly inhibiting their drug pump function in cancer cells (15). Furthermore, ABCG2-transduced cells were found to be resistant to gefitinib (16), and expression of ABCG2, but not its nonfunctional mutant, protects EGFR signaling-dependent tumor cells from death on exposure to gefitinib, and this protection was reversed by the ABCG2-specific inhibitor Ko143 (15). These reports strongly suggested that ABCG2 can actively pump gefitinib out of the cells. In our previous study, we also found that erlotinib was also able to antagonize ABCB1- and ABCG2-mediated MDR, suggesting that it might be a substrate of these two transporters (17). Lapatinib is also a potent and reversible inhibitor that acts at the ATP-binding site of the tyrosine kinase domains of both EGFR and Her-2. It is conceivable that lapatinib may inhibit functions of ABC transporters by binding to their ATP-binding sites. These have spurred efforts to investigate whether lapatinib can enhance the efficacy of conventional chemotherapeutic drugs via interaction with ABC transporters in MDR cancer cells and tumor xenograft model.

Materials and Methods

Materials. [125I]Iodoarylazidoprazosin (IAAP; 2,200 Ci/mmol) and [3H]Mitoxantrone (4 Ci/mmol) and [3H]methotrexate (23 Ci/mmol) were obtained from Sigma Chemical Co. Laboratory, NIH, Bethesda, MD). Doxorubicin, paclitaxel, mitoxantrone, obtained from BDBiosciences. PE-conjugated mouse monoclonal anti-human EGFR antibody and mouse IgG2b isotype control were from R&D Systems. Fumitremorgin C (FTC) was synthesized by Thomas McCloud (Developmental Therapeutics Program, Natural Products Extraction Laboratory, Bethesda, MD). Doxorubicin, paclitaxel, mitoxantrone, 6-mercaptopurine, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), rhodamine 123, and other chemicals were obtained from Sigma Chemical Co.

Cell lines and cell culture. The following cell lines were cultured in essential medium containing 10% fetal bovine serum at 37°C in the presence of 5% CO2: the human breast carcinoma cell line MCF-7 and its doxorubicin-selected derivative ABCB1-overexpressing MCF-7/adr (18), the human epidermoid carcinoma cell line KB and its vincristine-selected derivative ABCB1-overexpressing KBv200 (19), and the colon carcinoma cell line S1 and its mitoxantrone-selected derivative ABCG2-overexpressing S1-M1-80 (20), HEK293/pCDNA3.1, ABCG2-482-R5, ABCG2-482-G2, and ABCG2-482-T7 cells were established by selection with G418 after transfecting HEK293 with either empty pCDNA3.1 vector or pCDNA3.1 vector containing full-length ABCG2 coding either arginine (R), glycine (G), or threonine (T) at amino acid 482 position, respectively, and were cultured in medium with 2 mg/ml G418 (21). All cells were grown in drug-free culture medium for >2 wk before assay.

Cytotoxicity assay. The MTT assay was used to access cytotoxicity (22, 23). In detail, cells were grown in 96-well microtiter plates. To determine the toxicity of lapatinib, various concentrations of lapatinib diluted with medium were added into the wells. To test the effect of lapatinib on the chemosensitivity of cancer cells, lapatinib was added to the medium with various concentrations of doxorubicin in MCF-7, MCF-7/adr, and MX, or topotecan in S1 or S1-M1-80 cells, respectively, and mitoxantrone and cisplatin in HEK293/pCDNA3.1, ABCG2-482-R5, ABCG2-482-G2, and ABCG2-482-T7 cells. The concentrations required to inhibit growth by 50% (IC50) were calculated from survival curves using the Bliss method (24). The degree of resistance was calculated by dividing the IC50 for the MDR cells by that of the parental sensitive cells. The degree of the reversal of MDR was calculated by dividing the IC50 for cells with the anticancer drug in the absence of lapatinib by that obtained in the presence of lapatinib.

Experimental animals. Athymic nude mice, 5 to 6 wk old and weighing 18 to 23 g (Center of Experimental Animals, Sun Yat-Sen University), were used for the KBv200 cell xenografts. All animals were provided with sterilized food and water.

MDR human carcinoma xenografts. The KBv200 cell xenograft model was established as described by Chen and colleagues (25). Briefly, KBv200 cells grown in vitro were harvested and implanted s.c. under the shoulder in the nude mice. When the tumors reached a mean diameter of 0.5 cm, the mice were randomized into four groups and treated with one of the following regimens: (a) saline (q3d × 4), (b) paclitaxel (18 mg/kg, i.p., q3d × 4), (c) lapatinib (100 mg/kg, p.o., q3d × 4), and (d) paclitaxel (18 mg/kg, i.p., q3d × 4) + lapatinib (100 mg/kg, p.o., q3d × 4, given 1 h before giving paclitaxel). The body weight of the animals was measured every 3 d to adjust the drug dosage. The two perpendicular diameters (4 and 8) were recorded every 3 d and tumor volume (V) was estimated according to the following formula (25):

\[
V = \frac{A \times B}{6} \times 2^{1/2}
\]

The curve of tumor growth was drawn according to tumor volume and time of implantation. The mice were anesthetized and killed when the mean of tumor weights was over 1 g in the control group. Tumor tissue was excised from the mice and weighted. The rate of inhibition (IR) was calculated according to the following formula (25):

\[
IR(\%) = 1 - \frac{\text{Mean tumor weight of experimental group}}{\text{Mean tumor weight of control group}} \times 100\%
\]

Doxorubicin and mitoxantrone accumulation. The intracellular doxorubicin accumulation in ABCB1-overexpressing MCF-7/adr cells and their parent sensitive MCF-7 cells was examined by flow cytometry (26). The logarithmically growing cells were treated with 0.625, 1.25, or 2.5 μmol/L of lapatinib at 37°C for 3 h. Then, 10 μmol/L doxorubicin was added to the medium and the incubation continued for another 3 h. The cells were then collected, centrifuged, and washed twice with cold PBS containing 10 μmol/L verapamil. Cells were resuspended in 200 μL PBS
and then analyzed by flow cytometry (Elite, Beckman Coulter), with an excitation wavelength of 488 nm (argon laser) for the mean fluorescence intensity (MFI) of intracellular doxorubicin. The relative value of drug accumulation was identified by dividing the MFI for each measurement by that of the ABCB1-expressing cells in the absence of lapatinib.

The accumulation of mitoxantrone in ABCG2-transfected cells was measured using \(^{3}H\)mitoxantrone. Confluent cells in 24-well plates were preincubated with or without lapatinib for 1 h at 37°C. To measure drug accumulation, the cells were then incubated with 0.2 μmol/L \(^{3}H\)mitoxantrone for 2 h in the presence or absence of lapatinib at 37°C. After washing twice with ice-cold PBS, the cells were lysed in 10 mmol/L Tris–HCl buffer (pH 7.4, containing 1% Triton X-100 and 0.2% SDS). Each sample was placed in scintillation fluid and radioactivity was measured in a Packard Tri-Carb 1900CA liquid scintillation analyzer from Packard Instrument Company, Inc.

Preparation of membrane vesicles and total cell lysates. Membrane vesicles were prepared by the nitrogen cavitation method as previously described (17, 27). Vesicles were stored at −80°C until ready for use. To prepare the total cell lysates, cells were harvested and rinsed twice with PBS. Cell extracts were prepared with radioimmunoprecipitation assay buffer (1× PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 100 μg/mL phenylmethylsulfonyl fluoride, 10 μg/mL aprotinin, 10 μg/mL leupeptin) for 30 min with occasional rocking and clarified by centrifugation at 12,000 × g at 4°C for 15 min. The supernatant containing total cell lysates was stored at −80°C until it was ready for use. The protein concentration was determined by Bradford method. High Five insect cells (Invitrogen) were infected with recombinant baculovirus carrying the human ABCB1 or ABCG2 cDNAs as described previously, and the membrane vesicles of High Five cells were prepared as previously described (28) and stored at −70°C.

In vitro transport assays. Transport assays were performed essentially using the rapid filtration method as previously described (17, 29). Membrane vesicles were incubated with various concentrations of lapatinib for 1 h on ice, and then transport reactions were carried out at 37°C for 10 min in a total volume of 50 μL medium [membrane vesicles 10 μg, 0.25 mol/L sucrose, 10 mmol/L Tris–HCl (pH 7.4), 10 mmol/L MgCl₂, 4 mmol/L ATP or 4 mmol/L AMP, 10 mmol/L creatine phosphate, 100 μg/mL creatine phosphokinase, and 0.5 μmol/L \(^{3}H\)methylthreonine or 0.25 μmol/L \(^{3}H\)GABA] for 30 min with occasional rocking and centrifuged at 12,000 × g at 4°C for 15 min. The supernatant containing total cell lysates was stored at −80°C until it was ready for use. The protein concentration was determined by Bradford method. High Five insect cells (Invitrogen) were infected with the recombinant baculovirus carrying the human ABCB1 or ABCG2 cDNAs with a His₃ tag at the COOH-terminal end ([(BV-MDR1[His₃]) or (BV-His₃)-ABCG2]) as described previously, and the membrane vesicles of High Five insect cells were prepared as previously described (28) and stored at −70°C.

ATPase assay of ABCB1 and ABCG2. The Vi-sensitive ATPase activity of ABCB1 and ABCG2 in the membrane vesicles of High Five insect cells was measured as previously described (30). The membrane vesicles (10 μg protein) were incubated in ATPase assay buffer (50 mmol/L MES (pH 6.8), 50 mmol/L KCl, 5 mmol/L sodium azide, 2 mmol/L EGTA, 2 mmol/L DTT, 1 mmol/L ouabain, 10 mmol/L MgCl₂) with or without 0.3 mmol/L vanadate at 37°C for 5 min and then incubated with different concentrations of lapatinib at 37°C for 3 min. The ATPase reaction was induced by the addition of 5 mmol/L Mg-ATP, and the total volume was 0.1 mL. After incubation at 37°C for 20 min, the reactions were stopped by loading 0.1 mL of 5% SDS solution. The liberated inorganic phosphate (P₀) was measured as described previously (17, 30).

Photoaffinity labeling of ABCB1 and ABCG2 with \(^{125}I\)IAAP. The photoaffinity labeling of ABCB1 and ABCG2 with \(^{125}I\)IAAP was performed as previously described (17, 31). We have used the crude membranes from MCF-7/Flv1000 cells expressing R82B ABCG2 and membrane vesicles of High Five insect cells expressing ABCB1 for photoaffinity labeling experiments. The membranes (50 μg protein) were incubated at room temperature with different concentrations of lapatinib in the ATPase assay buffer with \(^{125}I\)IAAP (7 mmol/L) for 5 min under subdued light. The samples were photo-cross-linked with 365 nm UV light for 10 min at room temperature. ABCG2 was immunoprecipitated using BXP21 antibody (32), whereas ABCB1 was immunoprecipitated as described previously except that C-219 antibody was used (30). The samples were subjected to SDS-PAGE using a 7% Tris-acetate NuPAGE gel, and the gels were dried and exposed to BioMax MR film (Eastman Kodak Co.) at −70°C for 8 to 12 h. The radioactivity incorporated into the ABCB1 or ABCG2 band was quantified using the Storm 860 PhosphorImager system and ImageQuant (Molecular Dynamics).

Reverse transcription-PCR. The cells were treated with lapatinib for 48 h. Total cellular RNA was isolated by Trizol Reagent (Life Technologies) RNA Extraction kit following the manufacturer’s instruction. cDNA libraries were prepared from drug-sensitive and MDR cells. Reverse transcription was done with reverse transcriptase (Promega Corp.). Oligonucleotide primers for ABCB1, ABCG2, and GAPDH were synthesized commercially (Invitrogen Corp.). The primers used were the following: ABCB1, 5′-CCCA-TCACTGCAATAGCAGG-3′ (sense) and 5′-GTCCTACCTGTCTGTCCTGA-3′ (antisense); ABCG2, 5′-TGCGGTATCAGGTGATGTA-3′ (sense) and 5′-GCCACGTGATTCTCCAAAC-3′ (antisense); and GAPDH, 5′-GAAGGT-GAAGGCGGATGCCT-3′ (sense) and 5′-GAAGATGTTGATGGGATTTC-3′ (antisense). Using the GeneAmp PCR System 9700 (PE Applied Biosystems), reactions were carried out for ABCB1, ABCG2, and GAPDH at 94°C for 2 min for initial denaturation and then at 94°C for 30 s, 56°C for 30 s, and 72°C for 1 min. After 35 cycles of amplification, additional extensions were done at 72°C for 10 min. Products were resolved and examined by 2% agarose gel electrophoresis (24).

Western blot analysis. To determine whether lapatinib affects the expression of ABCB1 or ABCG2, the cells were incubated with different concentrations of lapatinib for 48 h. To test whether lapatinib is able to block Akt or Erk1/2 phosphorylation, we incubated cells with different concentrations of lapatinib (0.625–2.5 μmol/L) for different periods (12–48 h). Then, the cells were harvested and rinsed twice with PBS. Cell extracts were prepared by incubating with buffer (1× PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 100 μg/mL phenylmethylsulfonyl fluoride, 10 μg/mL aprotinin, 10 μg/mL leupeptin) for 30 min with occasional rocking and centrifuged at 12,000 × g for 15 min at 4°C. Identical amounts (100 μg protein) of cell lysates were incubated at 37°C for 20 min and resolved by SDS-PAGE and electrophoretically transferred onto polyvinylidene difluoride membranes. After being incubated in blocking solution containing 5% nonfat milk in TBST buffer (10 mmol/L Tris–HCl (pH 8.0), 150 mmol/L NaCl, 0.1% Tween 20) for 1 h at 4°C, membranes were incubated with the appropriately diluted primary antibody. The expression of GAPDH was used as a loading control. The membranes were then incubated for 1 h with horseradish peroxidase–conjugated secondary antibody at 1:1,000 dilution. Proteins were detected by the enhanced chemiluminescence detection system (Amersham). Protein expression was quantified by Scion Image software (Scion Co.; ref. 33).

Flow cytometry. Single-cell suspensions were prepared by the addition of 0.5 mL of EDTA followed by three washes with an isotonic PBS buffer [supplemented with 0.5% bovine serum albumin (BSA)]. For EGFR flow cytometric analysis, −1 × 10⁶ MCF-7, MCF-7/adr, S1, and S1-M1-80 cells (100 μL) were incubated at 4°C for 45 min with 20 μL of R-PE–conjugated anti-human EGFR reagent. Following this incubation, cells were washed twice with PBS buffer (supplemented with 0.5% BSA) and the supernatant was discarded. Finally, the cells were resuspended in 400 μL PBS buffer for flow cytometric analysis. Isotype control samples were treated in an identical manner with PE-labeled mouse IgG2b antibody. For Her-2 expression analysis, 10 μL of PE-conjugated anti-human ErbB2 reagent were mixed with 25 μL of cells (4 × 10⁵/mL). After incubating for 45 min at 4°C, the cells were washed twice with PBS buffer (supplemented with 0.5% BSA) and resuspended in 400 μL PBS buffer for flow cytometric analysis. Isotype control samples were treated in an identical manner with PE-labeled mouse IgG2b antibody (34).

Statistical analysis. All experiments were repeated at least thrice and statistical significance was determined using the Student’s t test. Significance was determined at P < 0.05.

Results

Effect of lapatinib and chemotherapeutic agents in various MDR cells and their parental cells. We examined the cytotoxic
The cytotoxic effect of chemotherapeutic agents in MCF-7, MCF-7/adr, S1, and S1-M1-80 cells in the presence of 0.625, 1.25, and 2.5 mol/L of lapatinib was tested. The mean IC_{50} values of lapatinib alone in different cell lines using the MTT assay are shown in Table 1. In ABCB1-overexpressing MCF-7/adr cells, lapatinib produced a significant dose-dependent increase in the cytotoxicity of doxorubicin. In contrast, lapatinib only produced a ~2-fold sensitization to doxorubicin in the parental MCF-7 cells. Importantly, lapatinib, at the lowest concentration tested (0.625 mol/L), was still able to reverse resistance to doxorubicin.

**Table 1. Effect of lapatinib on reversing ABCB1- and ABCG2-mediated drug resistance**

<table>
<thead>
<tr>
<th>Compounds</th>
<th>IC_{50} ± SD, μmol/L (fold reversal)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MCF-7</td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>0.334 ± 0.026 (1.0)</td>
</tr>
<tr>
<td>+0.625 μmol/L lapatinib</td>
<td>0.148 ± 0.016* (2.3)</td>
</tr>
<tr>
<td>+1.25 μmol/L lapatinib</td>
<td>0.062 ± 0.029* (2.1)</td>
</tr>
<tr>
<td>+2.5 μmol/L lapatinib</td>
<td>0.155 ± 0.013* (2.2)</td>
</tr>
<tr>
<td>+2.5 μmol/L FTC</td>
<td>0.365 ± 0.072 (0.9)</td>
</tr>
<tr>
<td>Mitoxantrone</td>
<td>0.204 ± 0.051 (1.0)</td>
</tr>
<tr>
<td>+0.625 μmol/L lapatinib</td>
<td>0.055 ± 0.021* (3.7)</td>
</tr>
<tr>
<td>+1.25 μmol/L lapatinib</td>
<td>0.054 ± 0.019* (3.8)</td>
</tr>
<tr>
<td>+2.5 μmol/L lapatinib</td>
<td>0.035 ± 0.012* (5.9)</td>
</tr>
<tr>
<td>+2.5 μmol/L FTC</td>
<td>0.167 ± 0.012 (1.2)</td>
</tr>
<tr>
<td>Topotecan</td>
<td>0.084 ± 0.045 (1.0)</td>
</tr>
<tr>
<td>+0.625 μmol/L lapatinib</td>
<td>0.015 ± 0.007* (5.6)</td>
</tr>
<tr>
<td>+1.25 μmol/L lapatinib</td>
<td>0.014 ± 0.005* (6.0)</td>
</tr>
<tr>
<td>+2.5 μmol/L lapatinib</td>
<td>0.012 ± 0.006* (7.0)</td>
</tr>
</tbody>
</table>

**Table 2. Effect of lapatinib on reversing ABCG2-mediated resistance to mitoxantrone and cisplatin**

<table>
<thead>
<tr>
<th>Compounds</th>
<th>HEK293/pcDNA3.1</th>
<th>ABCG2-482-R5</th>
<th>ABCG2-482-G2</th>
<th>ABCG2-482-T7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitoxantrone</td>
<td>0.043 ± 0.004 (1.0)</td>
<td>0.694 ± 0.021 (1.0)</td>
<td>1.683 ± 0.004 (1.0)</td>
<td>1.060 ± 0.022 (1.0)</td>
</tr>
<tr>
<td>+2.5 μmol/L lapatinib</td>
<td>0.044 ± 0.003 (1.0)</td>
<td>0.177 ± 0.023 (3.9)*</td>
<td>0.219 ± 0.003 (7.7)*</td>
<td>0.192 ± 0.024 (5.3)*</td>
</tr>
<tr>
<td>+10 μmol/L lapatinib</td>
<td>0.047 ± 0.003 (0.9)</td>
<td>0.065 ± 0.022 (10.7)*</td>
<td>0.070 ± 0.006 (24.0)*</td>
<td>0.070 ± 0.002 (51.5)*</td>
</tr>
<tr>
<td>+2.5 μmol/L FTC</td>
<td>0.042 ± 0.006 (1.0)</td>
<td>0.071 ± 0.011 (9.8)*</td>
<td>0.192 ± 0.023 (16.3)*</td>
<td>0.087 ± 0.001 (12.2)*</td>
</tr>
<tr>
<td>+10 μmol/L erlotinib</td>
<td>0.042 ± 0.003 (1.0)</td>
<td>0.085 ± 0.002 (8.2)*</td>
<td>0.082 ± 0.001 (20.5)*</td>
<td>0.075 ± 0.004 (14.1)*</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>1.85 ± 0.175 (1.0)</td>
<td>1.89 ± 0.240 (10.0)</td>
<td>2.05 ± 0.265 (1.0)</td>
<td>1.83 ± 0.031 (1.0)</td>
</tr>
<tr>
<td>+10 μmol/L lapatinib</td>
<td>2.16 ± 0.233 (0.8)</td>
<td>1.59 ± 0.252 (1.2)</td>
<td>2.16 ± 0.173 (1.0)</td>
<td>1.51 ± 0.119 (1.2)</td>
</tr>
</tbody>
</table>

**NOTE:** Cell survival was determined by MTT assay as described in Materials and Methods. Data are the means ± SD of at least three independent experiments performed in triplicate. The fold reversal of MDR was calculated by dividing the IC_{50} for cells with the anticancer drug in the absence of lapatinib or FTC by that obtained in the presence of lapatinib or FTC.

*P < 0.01 versus that obtained in the absence of lapatinib.

*P < 0.05 versus that obtained in the absence of lapatinib.
IC50 values for mitoxantrone in the presence or absence of lapatinib at 10 μmol/L (Table 2). There was no significant difference in the IC50 values for mitoxantrone in the presence or absence of lapatinib in HEK293/pcDNA3 cells (Table 2). In addition, lapatinib did not significantly alter the IC50 values of cisplatin, which is not a substrate of ABCG2. These results suggest that lapatinib specifically enhances the sensitivity of ABCG2 substrates in cells expressing either wild-type or mutant R482G/T ABCG2.

Lapatinib enhances the accumulation of chemotherapeutic agents in MDR cells overexpressing ABCB1 and ABCG2. The results above indicated that lapatinib could enhance the sensitivity of MDR cells to certain chemotherapeutic agents. The mechanism by which this occurs is unknown. Therefore, we examined its effects on doxorubicin accumulation in ABCB1-expressing MCF-7/adr cells and parental MCF-7 cells. Figure 1A illustrates the effect of lapatinib on the accumulation of doxorubicin in the MCF-7/adr and MCF-7 cells. Doxorubicin accumulation was significantly higher (4.2-fold) in the sensitive MCF-7 cells than in the MDR MCF-7/adr cells. In contrast, the level of doxorubicin accumulation in the drug-sensitive MCF-7 cells was unaffected by 0.625, 1.25, or 2.5 μmol/L of lapatinib. In the absence of lapatinib, the level of doxorubicin accumulation was low in MCF-7/adr cells and lapatinib restored the level of doxorubicin accumulation to that of the parental cells in a dose-dependent manner. The intracellular accumulation of doxorubicin was 1.5-, 2.9-, and 3.6-fold higher in MCF-7/adr cells in the presence of 0.625, 1.25, or 2.5 μmol/L of lapatinib, respectively. As depicted in Fig. 1B, in all cells overexpressing ABCG2, lapatinib at 1 and 2.5 μmol/L produced a concentration-dependent increase in the intracellular accumulation of [3H]mitoxantrone, and the effects of lapatinib at 2.5 μmol/L were similar to that of FTC at 2.5 μmol/L. However, lapatinib did not significantly alter the intracellular accumulation of [3H]mitoxantrone in HEK293/pcDNA3.1 cells. These results show that lapatinib was able to increase intracellular accumulation of chemotherapeutic agents in cells expressing ABCB1 or ABCG2.
Lapatinib inhibits the transport of [3H]methotrexate and [3H]E217βG by wild-type ABCG2. To further confirm the effect of lapatinib on the transport activity of ABCG2, we used membrane vesicles prepared from HEK293/pcDNA3 and ABCG2-482-R5 cells to perform inhibition experiments. We chose these two cell lines as the rate of ATP-dependent uptake of [3H]methotrexate, an anticancer drug, and a substrate of ABCG2 in membranes isolated from HEK293/pcDNA3.1 cells was significantly different from membrane vesicles of ABCG2-482-R5 cells but not from membrane vesicles of ABCG2-482-G2 and ABCG2-482-T7 cell lines (17). The effect of lapatinib on the transport of methotrexate by ABCG2 was shown in Fig. 1C. The rates of [3H]methotrexate uptake were significantly inhibited by lapatinib in a concentration-dependent manner. Furthermore, the inhibitory effect of lapatinib on methotrexate transport by ABCG2 membrane vesicles is comparable with that of erlotinib and FTC (Fig. 1C). In addition, lapatinib produced a concentration-dependent inhibition of [3H]E217βG, another substrate of ABCG2 (data not shown). These transport results suggest that lapatinib inhibits the transport of [3H]methotrexate and [3H]E217βG in wild-type ABCG2-482-R5-expressing cells.

Lapatinib activates the ATPase activity of ABCB1 and ABCG2. The drug efflux function of ABCB1 and ABCG2 is linked to ATP hydrolysis, which is stimulated in the presence of ABCB1 and ABCG2 substrates. To assess the effect of lapatinib on the ATPase activity of ABCB1 and ABCG2, we measured ABCB1- and ABCG2-mediated ATP hydrolysis using various concentrations of lapatinib under conditions that suppressed the activity of other major membrane ATPases. As shown in Fig. 2, lapatinib affected the ATPase activity of ABCB1 (Fig. 2A) and ABCG2 (Fig. 2B) in a concentration-dependent manner. Furthermore, the maximum ATPase activities of ABCB1 and ABCG2 in the presence of lapatinib were up to 42.9 ± 1.9 and 64.9 ± 1.7 nmol Pi/mg protein/min, respectively. Interestingly, lapatinib significantly stimulates the ATPase activities of ABCG2 at extremely low concentrations. This is not easily observed in Fig. 2B (inset). Consequently, only the low concentrations of lapatinib affecting the ATPase of ABCG2 are presented in Fig. 2B (inset). These data indicated that lapatinib may be a substrate of ABCB1 and ABCG2.

Lapatinib affects the photolabeling of ABCB1 and ABCG2 with [125I]IAAP. ABCB1 and ABCG2 can be photolabeled by a photoaffinity analogue of prazosin, [125I]IAAP, and their substrates
as well as inhibitors can compete for $[^{125}]$IAAP labeling of ABCB1 and ABCG2 (32). We therefore examined the photolabeling of ABCB1 and ABCG2 with $[^{125}]$IAAP by incubating membrane vesicles in the presence of various concentrations of lapatinib to primarily understand the physical interaction of lapatinib with the substrate interaction sites of ABCB1 and ABCG2. As indicated in Fig. 2, lapatinib strongly inhibited the photoaffinity labeling of ABCB1 (Fig. 2C) and ABCG2 (Fig. 2D) with $[^{125}]$IAAP in a concentration-dependent manner. The concentration of lapatinib required for 50% inhibition of photolabeling of ABCB1 and ABCG2 with $[^{125}]$IAAP was 2.8 ± 0.6 μmol/L and 3.2 ± 1.1 μmol/L, respectively. The results suggest that lapatinib binds to both the ABCB1 and ABCG2 substrate-binding site(s) with high affinity.

**EGFR and Her-2 status and effect of lapatinib on the blockade of Akt and Erk1/2 phosphorylation.** Using the MTT assay as an index of cytotoxicity, we observed that lapatinib alone does not produce significant cytotoxic effects in MCF-7 and S1 cell lines. However, nontoxic concentrations of lapatinib significantly enhance the cytotoxic effects of doxorubicin in MCF-7 cells, whereas FTC does not significantly enhance the cytotoxic effects of doxorubicin in MCF-7 cells (Table 1). To determine whether the relative lack of cytotoxicity produced by lapatinib is related to the expression of EGFR and/or Her-2, we used flow cytometry to detect EGFR and Her-2 in MCF-7 and S1 cell lines (Fig. 3B). Calu-3, a positive control cell line, expressed relative high levels of both EGFR (66.6 ± 2.8%) and Her-2 (97.5 ± 1.2%). The expression level of EGFR in S1 cells (65.0 ± 4.9%) is significantly higher than that in S1-M1-80 cells (37.6 ± 2.5%), whereas the expression level of Her-2 in S1 cells (29.3 ± 3.1%) is significantly lower than that in S1-M1-80 cells (49.3 ± 6.6%). MCF-7 cell expressed low levels of EGFR (10.8 ± 2.7%), whereas the MCF-7/adr cell line showed high expression (65.0 ± 4.5%). However, the MCF-7 (28.8 ± 2.2%) and MCF-7/adr (8.2 ± 0.5%) cell lines expressed low levels of Her-2. These results indicated that lapatinib potentiates the cytotoxic effects of anticancer drugs independent of the level of EGFR and Her-2 expression. Furthermore, we tested whether the concentrations of lapatinib that we used in our experiments can inhibit the phosphorylation of Akt or Erk1/2. As shown in Fig. 3A, lapatinib did not significantly block the phosphorylation of Akt and Erk1/2 in any of the four cell sublines. This result suggested that lapatinib-induced enhancement of the cytotoxicity of chemotherapeutic agents in MCF-7, MCF-7/adr, S1, and S1-M1-80 cells is not due to its antagonism of EGFR and Her-2 receptors.

**Effect of lapatinib on the expression of mRNA and protein levels of ABCB1 and ABCG2.** The reversal of ABC transporter-mediated MDR can be achieved either by decreasing transporter expression or by inhibiting function. Therefore, we determined the effect of lapatinib on the expression level of mRNA and protein levels using reverse transcription-PCR (RT-PCR) and Western blot, respectively. Our results showed that no marked difference in ABCB1 or ABCG2 expression at the mRNA (Fig. 3C) or protein level (Fig. 3D) was observed in MCF-7/adr cells (top) or S1-M1-80 cells (bottom) treated with lapatinib for 48 h compared with untreated cells. These results provide evidence that lapatinib does not affect the expression of ABCB1 and ABCG2. Thus, it mediates the reversal of MDR by inhibiting the function of ABCB1 and ABCG2.

**Lapatinib reverses ABCB1-mediated MDR in vivo.** We examined the efficacy of lapatinib in vivo to reverse the resistance to paclitaxel using established KBv200 cell xenografts in nude mice. There was no significant difference in tumor size between animals treated with saline, lapatinib, or paclitaxel alone. However, the
A combination of lapatinib and paclitaxel produced a significant greater inhibitory effect on tumor growth compared with animals treated with only saline, paclitaxel, or lapatinib ($P < 0.05$; Fig. 4) and the inhibition rate was 50.1%. In addition, at the doses tested, no mortality or significant decrease in body weight was associated with the combination treatments, suggesting that the combination regimen did not result in increased toxicity.

**Discussion**

Lapatinib is an inhibitor of the intracellular tyrosine kinase domains of both the EGFR and Her-2 receptors. Mutations or dysregulation in these receptors has been shown to play a role in the development of certain cancers. Lapatinib was approved for use in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpressed Her-2 and those who had received prior therapy with an anthracycline, a taxane, and trastuzumab. As the new TKIs are being introduced into the clinic, a significant effort will be directed toward increasing the anticancer activity of conventional chemotherapeutic agents or restoring chemosensitivity of resistant cancer cells to conventional chemotherapeutic agents. Our results showed for the first time that lapatinib had potent reversing activity in both ABCB1- and ABCG2-expressing MDR cells in vitro. Lapatinib, however, had no significant reversal effect in ABCC4-overexpressing NIH3T3/ABCC4-2 cells and lung cancer-resistant protein-overexpressing SW1573/2R1220 cells. Although lapatinib slightly enhanced the cytotoxicity of doxorubicin, mitoxantrone, and topotecan in drug-sensitive MCF-7 and S1 cells, respectively, lapatinib significantly potentiated the cytotoxicity of conventional chemotherapeutic agents in ABCB1- and ABCG2-overexpressing MDR cells to a much greater extent. Furthermore, lapatinib did not significantly alter cellular sensitivity to non-ABCB1 or non-ABCG2 substrates. Although the concentrations of lapatinib used in the current study (up to 2.5 μmol/L for MCF-7 and S1 cells) have been reported to be sufficient to block the EGFR signaling pathway, we did not observe any significant effect on the growth and survival of cells (Supplementary Fig. S1 and S2). In addition, we found that 2.5 μmol/L lapatinib does not block the phosphorylation of Akt and Erk1/2 (Fig. 3A) in MCF-7 and S1 cell lines. Thus, the potentiation of the cytotoxic effects of doxorubicin by lapatinib in MCF-7 cells may not be related to the antagonism of EGFR or Her-2 receptors. It is possible that this effect may be generated by a nonspecific cytotoxic mechanism or other unknown action of the drug. To determine if the in vitro effects of lapatinib can be extended to an in vivo paradigm, we have examined the effect of lapatinib on the antitumor activity of paclitaxel in xenograft model in mouse. Indeed, our results indicated that the combination of lapatinib with paclitaxel results in markedly enhanced antitumor activity of paclitaxel in an ABCB1-overexpressing tumor xenograft model (Fig. 4A and B).

Our results suggest that lapatinib significantly potentiated the toxicity of established ABCB1 or ABCG2 substrates in ABCB1- or ABCG2-overexpressing MDR cells unrelated to its inhibitory action of tyrosine kinase. Several groups have published in vitro data that support our findings. Coley and colleagues (36) reported that the addition of GW282974A, an analogue of lapatinib, to

---

5 Unpublished data.

---

**Figure 4.** Potentiation of antitumor effects of paclitaxel by lapatinib in a xenograft model of KBv200 cells in athymic nude mice. The experiment was carried out using athymic mice implanted s.c. with KBv200 cells. A, changes in tumor volume with time. Points, mean tumor volume for each group in 10 to 11 mice after implantation; bars, SD. B, tumor sizes. The picture was taken on the 17th day after implantation. The doses were as follows: lapatinib (100 mg/kg, p.o., q3d × 4) and paclitaxel (18 mg/kg, i.p., q3d × 4) + lapatinib (100 mg/kg, p.o., q3d × 4, given 1 h before paclitaxel administration).
paclitaxel resulted in a synergistic inhibition of cell survival in
ABCBI-expressing human ovarian cancer cell line PE01taxR. The
dual EGFR and Her-2 directed small-molecule TKI CI1033
enhanced the uptake and cytotoxicity of SN-38 and topotecan
in ABCG2-expressing glioblastoma T98G cells, colorectal carcino-
ma HCT8 cells, and ABCG2-transfected MDA-MB-231 cells (37).
Recently, Polli and colleagues (38) reported that lapatinib is a
substrate of ABCB1 and ABCG2 and an inhibitor of ABCB1 and
ABCG2 (IC50 values of 3.9 and 0.025 μmol/L, respectively). Their
results are not only consistent with our findings that lapatinib
is an inhibitor of ABCB1 and ABCG2, but their data are also in
agreement with our findings that low concentrations of lapatinib
are able to stimulate the ATPase activity of ABCG2 (Fig. 2A
and B) and inhibit the photolabeling of ABCB1 and ABCG2 with
IAAP (Fig. 2C and D), indicating that lapatinib directly interacts
with these transporters. Taken as a whole, these data suggest that
the pharmacokinetics of conventional chemotherapeutic agents
that are affected by ABC transporters may be altered in the
presence of lapatinib.

Clinical studies have also hinted at interactions between
lapatinib and ABC transporters. Lapatinib has been shown to
have clinical benefit in patients with brain-metastasized breast
cancer, increasing drug penetration across the blood-brain barrier,
presumably via inhibition of ABCB1 (37). The combination of
lapatinib and tamoxifen and ABCB1 substrate or conventional
chemotherapeutic agents, such as paclitaxel and doxorubicin,
may be active against hormone-refractory and chemotherapeutic drug-
resistant metastasized breast cancer (14, 39–41). In the phase I
study, when compared with irinotecan alone, the coadministration
of lapatinib and irinotecan significantly increased the area under
the plasma concentration-time curve of SN-38, the active
metabolite of irinotecan, which is an ABCB1 and ABCG2 substrate
(42). Despite the aforementioned promising findings, the authors
of these articles did not propose any clear mechanisms to explain
the synergy between lapatinib and chemotherapeutic agents.
However, in human pharmacokinetic studies, the highest peak
plasma lapatinib level was ~3 μmol/L, the half-life was ~17 h,
and steady-state concentrations were achieved after 6 to 7 days
of once-daily dosing (43, 44). These data suggest that the in vitro
concentrations of lapatinib used in our experiments are similar
to those obtained in plasma after therapeutic treatment. Thus,
it is possible that lapatinib affects chemosensitivity of refractory
or resistant cancer cells through its interaction with ABC
transporters.

Recently, Cusatis and colleagues (45) reported that one common
functional single-nucleotide polymorphism in the ABCG2 gene,
ABCG2 421C→A (Q141K), is associated with diarrhea, a gefitinib-
induced adverse effect, and led to a high risk of diarrhea in patients
-treated with oral gefitinib. The same group also reported that
this functional variant of ABCG2 was associated with a greater
accumulation of gefitinib at steady state and this may be relevant
to toxicity and antitumor activity of EGFR TKIs (46). These findings
suggest that the functional variants of ABCG2 in patients may
affect the pharmacokinetics and pharmacodynamics of not only
established ABCG2 substrates, such as camptothecins and mito-
xantrone, but also novel molecular target anticancer drugs, such
as gefitinib and lapatinib. Therefore, these functional single-
nucleotide polymorphisms can cause alterations in the adverse
events and therapeutic effects of chemotherapy. Similar to
gefitinib, the most frequent adverse effects of lapatinib in patients
are skin rash and diarrhea (47). Thus, these functional single-
nucleotide polymorphisms of ABCG2 in patients may also affect
the pharmacokinetics and pharmacodynamics of lapatinib, re-
sulting in an attenuation of its adverse events and therapeutic
effects.

The expression of the Arg482 → Gly482, and Thr482 → variant forms
of ABCG2 has been shown to confer greater resistance to some
substrates, such as mitoxantrone, and the sensitivity to some
ABCG2 modulators is decreased compared with the wild-type form
(48–50). Our results showed that lapatinib significantly enhances
the sensitivity of ABCG2 substrates not only in cells overexpressing
wild-type but also in the R482G/T variants of ABCG2. Mechanis-
tically, similar to other MDR inhibitors, lapatinib may be able to
reverse ABCB1- or ABCG2-mediated drug resistance by inhibiting
drug efflux. Consistent with this hypothesis, we found that
incubating MDR cells (such as MCF-7/adr and S1-M1-80 cells)
concomitantly with conventional chemotherapeutic drugs (sub-
strates of ABC transporters) and lapatinib resulted in a higher
intracellular drug accumulation in ABCB1- and ABCG2-expressing
cells than cells incubated with drug alone (Fig. 1A and B). A similar
result was obtained when we examined accumulation of rhoda-
mine 123 in ABCB1-expressing cells (data not shown). Further-
more, the transport of E717G and methotrexate inhibited by
lapatinib in a concentration-dependent manner in membrane
vesicles overexpressed wild-type ABCG2. However, the majority of
substrates that interact with the ABC drug transporters stimulate
ATP hydrolysis, and the fact that lapatinib stimulated the ATP
hydrolysis of both ABCB1 and ABCG2 suggested that it behaved
similarly to other known substrates of these transporters. These
data led us to speculate that lapatinib interacts directly with the
transporters. Indeed, this was confirmed by the finding that
lapatinib significantly inhibited the binding of the compound IAAP,
which photolabels the drug substrate–binding site of ABCB1 and
ABCG2. Lapatinib, however, had no significant effect on the
expression of ABCB1 in MCF-7/adr cells and ABCG2 in S1-M1-80
cells (Fig. 3C and D). These results suggested that lapatinib
reverses ABCB1- and ABCG2-mediated MDR by inhibiting the
function as opposed to expression of these two pumps. The
expression of EGFR and Her-2 (Fig. 3A) did not significantly alter
lapatinib toxicity in MCF-7/adr and S1-M1-80 cells or parental
MCF-7 and S1 cells (Supplementary Fig. S1). Additional in vitro
studies in cell lines expressing wild-type and mutant EGFR may be
useful to determine if there is a difference in the efficacy between
tumors expressing wild-type or mutant EGFR. The observed
toxicity of lapatinib at such relatively high concentrations may be
generated by a non-EGFR phosphorylation pathway. However, in
this study, we did not examine the potential mechanisms of
lapatinib toxicity in our cell lines.

In conclusion, lapatinib may inhibit cellular ABCB1 and ABCG2
functions at clinically relevant concentrations. The inhibition of
drug efflux as a result of direct interaction of lapatinib with ABCB1
or ABCG2 may lead to increased clinical response when combined
with conventional chemotherapeutic agents. Our analysis of the
reversal effect of lapatinib in tumor xenograft model indicates
that combination of lapatinib with other anticancer drugs may
be important in surmounting clinical resistance in cancer chemo-
therapy.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.
Cancer Research

Acknowledgments

References


The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Susan E. Bates (National Cancer Institute, NIH) for S1 and S1-M1-80 cells and FTC, Dr. Somnath Pal (St. John’s University) for statistical analyses, Dr. Jian-je Zhang (Sun Yat-Sen University) for technical assistance, and Tong Shen (St. John’s University) and Yuanmin (Mimi) Chen (Montgomery High School, Skillman, NJ) for editorial assistance with the manuscript.

Downloaded from cancerres.aacrjournals.org on April 8, 2017. © 2008 American Association for Cancer Research.
Correction: Reversal of Multidrug Resistance by Lapatinib

In the article on reversal of multidrug resistance by lapatinib in the October 1, 2008 issue of Cancer Research (1), there is an error in Fig. 1A. The corrected figure appears below.

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
